Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety. Results: Five patients with genotype 1a and three patients with genotype 1b (RAV positive) received ledipasvir/sofosbuvir for 12 weeks. SVR12 rate was 100% (8/8). Eleven patients with genotype 1b were treatment-naïve and received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 91% (10/11). One patient experienced viral breakthrough without RAV at 12 weeks. Seven treatment-experienced patients with genotype 1b received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 85.7% (6/7). One patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks. Four patients with genotype 2a/2b received sofosbuvir plus ribavirin for 12 weeks. SVR12 rate was 100% (4/4). No serious adverse event-related discontinuations were noted. Conclusions: New direct acting antiviral treatment achieved high SVRs rates at 12 weeks in CHC patients with hemophilia without serious adverse events.
Abstract
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety. Results: Five patients with genotype 1a and three patients with genotype 1b (RAV positive) received ledipasvir/sofosbuvir for 12 weeks. SVR12 rate was 100% (8/8). Eleven patients with genotype 1b were treatment-naïve and received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 91% (10/11). One patient experienced viral breakthrough without RAV at 12 weeks. Seven treatment-experienced patients with genotype 1b received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 85.7% (6/7). One patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks. Four patients with genotype 2a/2b received sofosbuvir plus ribavirin for 12 weeks. SVR12 rate was 100% (4/4). No serious adverse event-related discontinuations were noted. Conclusions: New direct acting antiviral treatment achieved high SVRs rates at 12 weeks in CHC patients with hemophilia without serious adverse events.
참고문헌 (23)
- Kim DH, "Korea hemophilia foundation registry trends 1991-2012: patient registry, demographics, health services utilization", Haemophilia, 21, pp.e479~e480 (2015)
- 양서윤, "Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea", Clinical and Molecular Hepatology, 21(2), pp.125~130 (2015), 대한간학회
- Hyun Woong Lee, "Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response", Gut and Liver, 10(5), pp.661~662 (2016), 거트앤리버 발행위원회
- Walsh CE, "Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders", Haemophilia, 23, pp.198~206 (2017)
- McPhee F, "High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms", Adv Ther, 32, pp.637~649 (2015)
- Posthouwer D, "Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study", Blood, 109, pp.3667~3671 (2007)
- Tagliaferri A, "Mortality and causes of death in Italian persons with haemophilia, 1990-2007", Haemophilia, 16, pp.437~446 (2010)
- Poynard T, "Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups", Lancet, 349, pp.825~832 (1997)
- Fried MW, "Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin", Hepatology, 36(4 Pt 1), pp.967~972 (2002)
- Franchini M, "Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis", J Antimicrob Chemother, 61, pp.1191~1200 (2008)
- Wilde JT, "UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011", Haemophilia, 17, pp.e877~e883 (2011)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)
- AASLD, "IDSA HCV guidance panel", Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, 2015, pp.62, 932~954
- McQuaid T, "Sofosbuvir, a significant paradigm change in HCV treatment", J Clin Transl Hepatol, 3, pp.27~35 (2015)
- Jensen CM, "Ledipasvir-sofosbuvir: a once-daily oral treatment option for chronic hepatitis C virus genotype 1 infection", Pharmacotherapy, 36, pp.562~574 (2016)
- Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)
- Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", N Engl J Med, 370, pp.1483~1493 (2014)
- Kowdley KV, "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis", N Engl J Med, 370, pp.1879~1888 (2014)
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
- Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)
- Wang HL, "Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:systematic review and meta-analysis", J Gastroenterol Hepatol, 32, pp.45~52 (2017)
- Kao JH, "All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a subanalysis in Asian patients from the HALLMARK DUAL study", Liver Int, 36, pp.1433~1441 (2016)